Papautsky and team have received two NIH (National Institutes of Health) grants to begin and continue development of the sensor: 1) R21 two-year grant (September 2010-August 2012) worth $425,000; and 2) RO1 four-year grant (October 2013-2017) worth $1.55 million.
Three years ago, the NIH R21 grant allowed Papautsky the chance to demonstrate a proof-of-concept version of the sensor. In its early stages, the sensor posed a few obstacles including: 1) surface chemistry challenges; 2) the challenge of working with extremely small blood sample sizes (which are ideal for children); and 3) the challenges of working with biological samples due to the high concentrations of protein.
The most recent grant awarded to the team—the four-year RO1 grant—enables the team focus their efforts on the sensor’s prototype. They wish to reduce its size and make the sensor itself a USB port. The team plans to field test the sensor in Marietta, OH, where high concentrations of manganese can be found and is a growing problem to citizens’ health. UC has already filed provisional patents for the sensor.
Papautsky explains, "While we are still in the pre-commercialization stage, we are now positioned to fully develop the sensor system for point-of-care application. It shows great potential to generate significant revenue but more importantly, it will save human lives.”
This will be the third annual Cincinnati USA Innovation Awards, celebrating innovative companies and people that show how new ideas can be developed into fuel for the Tri-State's economic engine.
For more information about the development of the sensor, please visit: http://healthnews.uc.edu/news/?/23304/
For more information about the College of Engineering and Applied Science, please visit: http://ceas.uc.edu/
Select for print copy.